Innocent Biopharma

What Innocent Biopharma does

Inosan Biopharma is a privately held biotechnology company that develops and manufactures polyvalent equine-derived antivenoms for the treatment of snake bite envenomation and scorpion stings. The company's marketed portfolio comprises three core products — Inoserp MENA (covering 27 medically important snake species across the Middle East and North Africa), Inoserp PAN-AFRICA (covering 24 species across Sub-Saharan Africa), and Inoscorpi MENA (covering 10 scorpion species) — all built on a single proprietary platform that produces highly purified F(ab')2 immunoglobulin fragments (95% purity) at low protein content (<10%, <100 mg/mL) in a preservative-free, lyophilized formulation.

The underlying technology is a classical equine hyperimmune platform: horses are immunized with selected venoms, plasma is harvested, and pepsin digestion yields F(ab')2 fragments that are purified and freeze-dried. The lyophilized presentation is stable at room temperature up to 30°C (with excursions to 40°C), which eliminates cold chain dependency and enables distribution in tropical, resource-limited settings. Manufacturing is performed at a GMP-certified facility in Mexico City under COFEPRIS oversight (a WHO-recognized agency), with clinical evidence including <3% adverse-event rates for Inoserp MENA in Moroccan retrospective data and <1% serum sickness across both flagship products.

The business model is enterprise and government direct sales: products are sold to ministries of health, public health systems, and hospitals across 15+ countries in MENA and Sub-Saharan Africa. Pricing is not publicly disclosed. Beyond the three marketed products, the company is investing in a 12+ asset pipeline that extends the F(ab')2 platform into new geographies (Europe, Asia, South Africa, South America, North America), new species (coral snake, spider), and new indications including SARS-CoV-2, Ebola, diphtheria, and tetanus. Corporate functions are headquartered in Alcobendas (Madrid), Spain, with regional representation in Accra and Nairobi and sales offices in Denver and Paris.

Name

Innocent Biopharma

Legal name

Inosan Biopharma

Website

https://inosanbiopharma.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Inosan Biopharma is a private biotechnology company that develops and distributes GMP-certified equine-derived F(ab')2 polyvalent antivenoms for snake bites and scorpion stings, serving public health systems and hospitals across Sub-Saharan Africa and the MENA region.

Ownership category

akta.pro rank

Product category

Antivenom biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH)

akta.pro secondary industry

Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)

Keywords

• Polyvalent antivenoms
• Equine F(ab')2 immunoglobulins
• Snakebite envenoming therapy
• Scorpion antivenom biologics
• Lyophilized biological products

Headquarters

HQ city

Juarez

HQ country

Mexico

HQ region

Latin America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Antivenom Product Sales: Revenue generated from the sale of equine-derived antivenom products (Inoserp MENA, Inoserp PAN-AFRICA, Inoscorpi MENA) to healthcare facilities, hospitals, and government health ministries across endemic regions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Inosan Biopharma develops, manufactures, and distributes next-generation polyvalent equine antivenoms built on highly purified F(ab')2 immunoglobulin fragments. The marketed portfolio includes Inoserp MENA (snake bites, MENA region, 27 species), Inoserp PAN-AFRICA (snake bites, Sub-Saharan Africa, 24 species), and Inoscorpi MENA (scorpion stings, MENA region, 10 species), all supplied as lyophilized, room-temperature-stable injectables to ministries of health, hospitals, and clinics in endemic regions.

Product overview

Inosan Biopharma is a biotechnology company that develops and distributes antivenoms. The core product portfolio consists of three marketed polyvalent equine antivenom products: Inoserp MENA (for snake bites in Middle East & North Africa), Inoserp PAN-AFRICA (for snake bites in Sub-Saharan Africa), and Inoscorpi MENA (for scorpion stings in MENA region). All products are highly purified F(ab')2 immunoglobulin fragments manufactured under GMP standards. The company has an extensive development pipeline targeting additional geographic regions (Europe, Asia, South America, North America, South Africa) and venomous creatures (coral snakes, spiders), as well as antivirals for SARS-CoV-2 and Ebola, and antitoxins for diphtheria and tetanus.

Differentiator

Problem solved

Functional benefit

Brands

• Inoserp: Polyvalent equine antivenom product line for snake bites, including Inoserp MENA (Middle East & North Africa) and Inoserp PAN-AFRICA (Sub-Saharan Africa)
• Inoscorpi

Products and services

• Inoserp MENA (Middle East & North Africa) Polyvalent equine antivenom indicated for the treatment of snake bites in the Middle East and North Africa region. Covers 27 medically important snake species including Viperidae and Elapidae families, provided as a sterile, highly purified lyophilized preparation of equine F(ab')2 immunoglobulin fragments intended for hospitals, clinics, and public health systems in endemic MENA countries.
• Inoserp PAN-AFRICA Polyvalent equine antivenom indicated for the treatment of snake bites in Sub-Saharan Africa, covering 18 medically important snake species with cross-neutralization of 6 additional species (24 total). Made of highly purified equine F(ab')2 immunoglobulin fragments and supplied as a sterile lyophilized injection for hospitals, clinics, and public health systems across Sub-Saharan Africa.
• Inoscorpi MENA (Middle East & North Africa) Polyvalent equine antivenom indicated for the treatment of scorpion stings in the Middle East and North Africa region, covering 10 medically relevant scorpion species including Androctonus and Buthus genera. Supplied as a sterile, highly purified lyophilized preparation of equine F(ab')2 immunoglobulin fragments for hospitals and clinics in MENA countries.

Quantifiable outcome

• Inoserp MENA is effective in controlling thrombocytopenia in the large majority of patients based on 5-year retrospective data (2016-2020) from Moroccan poison center
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bharat Serums and Vaccines: Indian biopharmaceutical company producing equine-derived antivenoms (e.g., ASV) for the Indian subcontinent and export markets. Directly comparable in equine antivenom manufacturing and emerging-market distribution model.
• Vins Bioproducts: Indian manufacturer of equine polyvalent antivenoms and anti-snake venom serums. Directly comparable as a regional antivenom producer targeting endemic countries in Asia and Africa.
• Instituto Bioclon: Mexico-based antivenom manufacturer producing equine-derived antivenoms (e.g., Antivipmyn) for Latin America and other regions. Directly comparable to Inosan as a polyvalent equine antivenom producer serving endemic regions.
• Instituto Clodomiro Picado (University of Costa Rica): Costa Rican public manufacturer of equine-derived polyvalent antivenoms for Central and South America. Uses similar F(ab')2 equine immunoglobulin platform and serves endemic snakebite markets, making it a directly comparable antivenom producer.
• Butantan Institute: Brazilian public biomedical institute that manufactures polyvalent equine antivenoms and antitoxins for South America. Directly comparable due to its equine immunoglobulin platform and focus on snake/scorpion/spider antivenoms for endemic regions.
• MicroPharm (now part of BTG/Specialised Therapeutics): UK-based manufacturer of equine antivenoms (e.g., Vipera berus antivenom) and antitoxins using ovine/equine immunoglobulin fragment platforms. Directly comparable as a specialty equine antivenom/antitoxin producer.

Broad incumbents

• Pfizer (Anavip / CroFab): Global pharmaceutical company marketing CroFab (ovine) and Anavip (equine F(ab')2) antivenoms in the United States. Comparable as a large incumbent player in the antivenom market, though primarily focused on North America.
• CSL Seqirus / CSL Limited: Global biotherapeutics major with a broad antivenom portfolio and plasma-derived immunoglobulin capabilities. Comparable as a large incumbent in the antivenom/immunoglobulin space with much wider geographic reach.

Emerging players

• Rare Disease Therapeutics: US-based specialty pharma focused on niche antivenom and antidote products including CroFab distribution. Comparable as an emerging player in the specialty antivenom category with focus on the US market.

Regional players

• South African Vaccine Producers (Pty) Ltd: South African state-owned manufacturer of antivenoms (e.g., SAIMR polyvalent antivenom) for sub-Saharan Africa. Comparable as a regional antivenom producer targeting African snakebite markets, with potential overlap with Inosan's PAN-AFRICA franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/InosanBiopharma
• Facebookfacebook.com/InosanBiopharma
• LinkedInlinkedin.com/company/inosanbiopharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innocent Biopharma